ESH Video

ESH-ICML 12th International Conference CHRONIC MYELOID LEUKEMIA - Biological Basis of Therapy

ESH-ICML 12th International Conference CHRONIC MYELOID LEUKEMIA - Biological Basis of Therapy
September 24 - September 26, 2010 - Washington, United States
Chairs :


Despite the impressive clinical results of tyrosine kinase inhibitors in the management of patients with CML, many unresolved questions remain. This meeting brings together scientists with new data on the cellular, molecular and immune biology of CML, some of which may eventually translate into new therapeutic approaches that would enable the clinician to discontinue therapy with the expectation that the leukaemia would not recur.


Friday, September 24, 2010
08h15 - 08h20 Welcome to Washington J. Barrett (Bethesda)
08h20 - 08h45

Rowley Lecture - Chair: J.Goldman (London)

M. Talpaz (Ann Arbor)
Session I: Stem Cell Biology - Chair: John Goldman (London)
08h45 - 09h00 Ph-negative neoplasms T. Green (Cambridge, UK)
09h00 - 09h15 Ph + quiescent cells P. Neviani (Columbus)
09h15 - 09h30 Oncogene addiction in CML M. Deininger (Portland)
09h30 - 09h45 Relevance of BCR-ABL for survival of LSC V. Helgason (Glasgow)
09h45 - 10h00 The role of Musashi 2 in myeloid leukemia M. Kharas (Boston)
10h00 - 10h15 Regulation of survival in normal and CML cells F. Pellicano (Glasgow)
10h15 - 10h30 Altered trafficking and niche interactions in a CML mouse model R. Bhatia (Duarte)
10h30 - 10h45 ScITAxTRE-BCR-ABL inducible mouse model D. Reynaud (San Francisco)
10h45 - 11h00 BCR-ABL in Sca1 cells C. Vicente-Duenas (Salamanca)
11h00 - 11h30 Break with poster viewing
Session II: Targeting stem cells - Chair: Junia Melo (Adelaide)
11h30 - 11h45 IL1RAP T. Fioretos (Lund)
11h45 - 12h00 Targeting antiapoptotic proteins to eradicate quiescent CML progenitor cells B. Carter (Houston)
12h00 - 12h15 Beta arrestin M. Fereshteh (Durham)
12h15 - 12h30 NFkB in myeloid and lymphoid transformation and leukemogenesis R. Van Etten (Boston)
12h30 - 12h45 Hedgehog pathway M. Copland (Glasgow)
12h45 - 13h00 Targeting CML progenitors with ABL & JAK2 inhibitors X. Jiang (Vancouver)
13h00 - 14h30 Lunch with poster viewing
14h30 - 15h30 Brief Oral Session A - Chair: Jerry Radich (Seattle)
Abstract # 1 R. Arlinghaus (Houston)
Abstract # 3 E. Bolton (Philadelphia)
Abstract # 36 S. Li (Worcester)
Abstract # 15 Y. Dasgupta (Philadelphia)
Abstract # 19 C. Drullion (Bordeaux)
Abstract # 5 T. Brummendorf (Aachen)
Abstract # 37 L. Li (Duarte)
Abstract # 17 C. Quintarelli (Naples)
Abstract # 43 F. Nicolini ( Lyon)
Session III: Mathematical modeling - Chair : Tessa Holyoake (Glasgow)
15h30 - 15h45 Mathematical modeling of diversity in pre-existing resistance to BCR-ABL inhibitors J. Foo (Cambridge, USA)
15h45 - 16h00 Response dynamics of imatinib and nilotinib D. Dingli (Rochester, MN)
16h00 - 16h15 Short Break
Session IV: Kinase effects & Genomic instability - Chair: Danilo Perrotti (Columbus)
16h15 - 16h30 Molecular mechanism of leukemogenicity O. Hantschel (Vienna)
16h30 - 16h45 Ikaros alterations in Ph+ALL C. Mullighan (Memphis)
16h45 - 17h00 Mutator phenotype of BCR-ABL Y. Maru (Tokyo)
17h00 - 17h15 Mismatch repair protein dysfunction T. Stoklosa (Warsaw)
17h15 - 17h30 Next generation sequencing identifies novel molecular alterations in PH+ALL I. Iacobucci (Bologna)
17h30 - 17h45 Mechanisms of genomic instability in CML stem cells P. Kopinski (Philadelphia)

Saturday, September 25, 2010

Session V: Immunologic aspects of CML - Chair: Tessa Holyoake (Glasgow)
08h30 - 08h45 Target for immunotherapy in CML J. Barrett (Bethesda)
08h45 - 09h00 WT1 D. Scheinberg (New York)
09h00 - 09h15 BMI 1 A. Yong (Bethesda)
09h15 - 09h30 NK gene polymorphisms in CML K. Rezvani (London)
09h30 - 10h00 Break with poster viewing
Session VI: Resistance including TKI mutations - Chair: Angelo Carella (Genoa)
10h00 - 10h15 B-catenin involved in resistance to imatinib J. Wang (San Diego)
10h15 - 10h30 PI3K in maintaining LSC A. Hirao (Kanagawa)
10h30 - 10h45 Massively parellel sequencing in CML S. Soverini (Bologna)
10h45 - 11h00 Mutations relevant to 2G-TKI S. Branford (Adelaide)
11h00 - 11h15 NRF2 in imatinib resistance F. Rassool (Baltimore)
11h15 - 11h30 Targeting kinase and BCL6 dependent feedback M. Müschen (Los Angeles)
11h30 - 12h30 Brief Oral Session B - Chair: Tomasz Skorski (Philadelphia)
Abstract # 24 H. Ming (London)
Abstract # 27 D.H. D. Kim (Seoul)
Abstract # 39 A. Morotti (Turin)
Abstract # 44 T. O´Hare (Portland)
Abstract # 45 E. Pietras (San Francisco)
Abstract # 20 C. Quintarelli (Naples)
Abstract # 30 J. Khorashad (London)
Abstract # 52 A. Turhan (Poitiers)
Abstract # 47 A. Reid (London)

12h30 - 13h30

Lunch with poster viewing
Session VII: Progession to advanced phase - Chair: François Guillot (Poitiers)
13h30 - 13h45 Lin28 in malignant transformation J. Power (Boston)
13h45 - 14h00 Model of blastic crisis J. Rusert (San Diego)
14h00 - 14h15 PP2A C. Lucas (Liverpool)
14h15 - 14h30 Developmental mechanisms in CML progression T. Reya (Durham)
Session VIII: Diagnostic tests and prognostic markers - Chair: Timothy Hughes (Adelaide)
14h30 - 14h45 Single cell genotyping J. Radich (Seattle)
14h45 - 15h00 Mechanisms of resistance other than KD mutations F.-X. Mahon (Bordeaux)
15h00 - 15h15 DNA based PCR for monitoring A. Morley (Adelaide)
15h15 - 15h30 Antibodies to BCR-ABL H. Wai (San Jose)
15h30 - 15h45 Definitions of CMR A. Hochhaus (Jena)
15h45 - 16h00 Patient specific approach to optimising TKI therapy D. White (Adelaide)
16h00 - 16h15 Prognostic value of MDR1 M. Müller (Mannheim)
16h15 - 16h45 Break with poster viewing
16h45 - 17h45 Brief Oral Session C - Chair: Simona Soverini (Bologna)
Abstract # 6 A. Carella (Genoa)
Abstract # 53 D. Yeung (Adelaide)
Abstract # 18 H. De Lavallade (London)
Abstract # 54 B. Zhang (Duarte)
Abstract # 55 Y. Zhao (Suzhou)
Abstract # 48 P. Rousselot (Chesnay)
Abstract # 40 S. Mustjoki (Helsinki)
Abstract # 13 D. Cilloni (Turin)

Sunday, September 26, 2010

Session IX: New drugs in development - Chair: Rudiger Hehlmann
08h30 - 08h45 Bosutinib C. Gambacorti (Monza)
08h45 - 09h00 Ariad, DCC 2036, other new agents J. Cortes (Houston)
09h00 - 09h15 Omacetaxine J. Apperley (London)
09h15 - 09h30 Smo inhibitors G. Martinelli (Bologna)
09h30 - 09h45 Break

Session X: Current clinical controversies - Chair: Michele Baccarani (Bologna)

09h45 - 10h15 Is MMR better than CCyR ? G. Rosti (Bologna) &
G. Saglio (Turin)
10h15 - 10h45 Starting with imatinib or 2G-TKI ? J. Cortes (Houston) &
C. Schiffer (Detroit)
10h45 - 11h15 Should interferon come back now? F. Guilhot (Poitiers) &
A. Hochhaus
11h15 - 11h30 Does CMR have any real relevance? T. Hughes (Adelaide)
11h30 - 11h45 The ideal clinical trial for the coming decade S. O’Brien (Newcastle)
11h45 - 12h00 Closing comments including short musical interlude J. Goldman (London) &
C. Schiffer

Abstract submission




Grand Hyatt Washington DC
1000 H Street, NW
Washington, DC 20001

Corporate partners